(Reuters) - Gary Stiles, chief medical officer of Wyeth, told reporters
in a conference call the FDA has requested a new safety trial
of Pristiq for hot flashes due to elevated liver enzymes seen
in three women among 2,000 tested in Wyeth-sponsored trials of
the drug for a common symptom of menopause.
" liver enzymes are not an uncommon phenomenon"
in drug trials, Stiles said. He said elevated levels of the
enzymes -- which are considered a marker of potential damage to
the liver -- returned to normal levels when patients stopped
taking Pristiq.
Read more at Reuters.com Market News
in a conference call the FDA has requested a new safety trial
of Pristiq for hot flashes due to elevated liver enzymes seen
in three women among 2,000 tested in Wyeth-sponsored trials of
the drug for a common symptom of menopause.
" liver enzymes are not an uncommon phenomenon"
in drug trials, Stiles said. He said elevated levels of the
enzymes -- which are considered a marker of potential damage to
the liver -- returned to normal levels when patients stopped
taking Pristiq.
Read more at Reuters.com Market News
No comments:
Post a Comment